Safety profile of the oral iron chelator deferiprone: a multicentre study.

Abstract:

:In previous trials, the orally active iron chelator deferiprone (L1) has been associated with sporadic agranulocytosis, milder forms of neutropenia and other side-effects. To determine the incidence of these events, we performed a multicentre prospective study of the chelator. Blood counts were performed weekly, and confirmed neutropenia mandated discontinuation of therapy. Among 187 patients with thalassaemia major, the incidence of agranulocytosis (neutrophils < 0.5 x 109/l) was 0.6/100 patient-years, and the incidence of milder forms of neutropenia (neutrophils 0.5-1.5 x 109/l) was 5.4/100 patient-years. All cases of neutropenia resolved after interruption of therapy. Neutropenia occurred predominantly in non-splenectomized patients. Nausea and/or vomiting occurred early in therapy, was usually transient and caused discontinuation of deferiprone in three patients. Mild to moderate joint pain and/or swelling did not require permanent cessation of deferiprone and occurred more commonly in patients with higher ferritin levels. Mean alanine transaminase (ALT) levels rose during therapy. Increased ALT levels were generally transient and occurred more commonly in patients with hepatitis C. Persistent changes in immunological studies were infrequent, although sporadic abnormalities occurred commonly. Mean zinc levels decreased during therapy. Ferritin levels did not change in the overall group but decreased in those patients with baseline levels > 2500 microgram/l. This study characterized the safety profile of deferiprone, and, under the specific conditions of monitoring, demonstrated that agranulocytosis is less common than previously predicted.

journal_name

Br J Haematol

authors

Cohen AR,Galanello R,Piga A,Dipalma A,Vullo C,Tricta F

doi

10.1046/j.1365-2141.2000.01866.x

subject

Has Abstract

pub_date

2000-02-01 00:00:00

pages

305-12

issue

2

eissn

0007-1048

issn

1365-2141

pii

bjh1866

journal_volume

108

pub_type

杂志文章,多中心研究
  • Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON)

    abstract::The question as to whether autologous stem cell transplantation (SCT) after consolidation chemotherapy improves the probability of survival of patients with acute myeloid leukaemia (AML) in first remission has not been settled. Here, we present the results of a phase III study conducted in newly diagnosed adult AML pa...

    journal_title:British journal of haematology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2141.2004.05282.x

    authors: Breems DA,Boogaerts MA,Dekker AW,Van Putten WL,Sonneveld P,Huijgens PC,Van der Lelie J,Vellenga E,Gratwohl A,Verhoef GE,Verdonck LF,Löwenberg B

    更新日期:2005-01-01 00:00:00

  • Generation of the NUP98-HOXD13 fusion transcript by a rare translocation, t(2;11)(q31;p15), in a case of infant leukaemia.

    abstract::We report a case of de novo acute myelomonocytic leukaemia with the t(2;11)(q31;p15) translocation in a Japanese female infant. The NUP98-HOXD13 fusion transcript generated by the translocation was detected in the patient's bone marrow cells by reverse transcription-polymerase chain reaction (RT-PCR). Additionally, ec...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2141.2000.02172.x

    authors: Shimada H,Arai Y,Sekiguchi S,Ishii T,Tanitsu S,Sasaki M

    更新日期:2000-07-01 00:00:00

  • L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.

    abstract::Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis (EBV-HLH) is one of the most common subtypes of secondary HLH. However, more than 30% of patients do not respond to traditional treatment. Here, we investigated the efficacy and safety of the L-DEP regimen as a salvage therapy for paediatric refractory ...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.16861

    authors: Zhao Y,Li Z,Zhang L,Lian H,Ma H,Wang D,Zhao X,Zhang Q,Wang T,Zhang R

    更新日期:2020-11-01 00:00:00

  • Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia.

    abstract::Cytogenetic deletions of the short arm of chromosome 12 are common recurring alterations found in a wide range of haematological neoplasias, including childhood acute lymphoblastic leukaemia (ALL), the most frequent paediatric malignancy. Such a loss of genetic material suggests the presence of a tumour suppressor gen...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.1997.3663180.x

    authors: Baccichet A,Sinnett D

    更新日期:1997-10-01 00:00:00

  • Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. I. Ultrastructural morphology and cytochemistry.

    abstract::A systematic analysis of the blast cell population was carried out on samples from 50 patients suffering from blast transformation of chronic granulocytic leukaemia (CGL) (31) and of myelofibrosis (4), acute myelofibrosis (AM) (11) and undifferentiated acute leukaemia (4). Transmission electron microscopy (TEM), used ...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1985.tb02994.x

    authors: Polli N,O'Brien M,Tavares de Castro J,Matutes E,San Miguel JF,Catovsky D

    更新日期:1985-02-01 00:00:00

  • Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients.

    abstract::Monoclonal gammopathy of undetermined significance (MGUS) has been associated with an increased risk of thrombosis. We carried out a retrospective multicentre cohort study on 1491 patients with MGUS. In 49 patients (3.3%) MGUS was diagnosed after a thrombotic event. Follow-up details for a period of at least 12 months...

    journal_title:British journal of haematology

    pub_type: 杂志文章,多中心研究

    doi:10.1111/bjh.12168

    authors: Za T,De Stefano V,Rossi E,Petrucci MT,Andriani A,Annino L,Cimino G,Caravita T,Pisani F,Ciminello A,Torelli F,Villivà N,Bongarzoni V,Rago A,Betti S,Levi A,Felici S,Gentilini F,Calabrese E,Leone G,Multiple Myeloma G

    更新日期:2013-03-01 00:00:00

  • Chromosomal abnormalities in systemic amyloidosis.

    abstract::Primary systemic amyloidosis (AL) is a plasma cell disorder characterized by deposition of monoclonal light chains in different organ systems. Although multiple and complex numerical chromosomal abnormalities have been described in patients with multiple myeloma, it is currently unknown whether such changes occur in s...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.1998.01034.x

    authors: Fonseca R,Ahmann GJ,Jalal SM,Dewald GW,Larson DR,Therneau TM,Gertz MA,Kyle RA,Greipp PR

    更新日期:1998-12-01 00:00:00

  • Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis.

    abstract::Conflicting evidence exists on the epidemiology of type 2 diabetes mellitus (T2DM) among patients with sickle cell disease (SCD). This study measured the prevalence, incidence and clinical outcomes associated with T2DM in a large US population of commercially-insured adults aged ≥20 years with SCD between 2009 and 201...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.15773

    authors: Zhou J,Han J,Nutescu EA,Galanter WL,Walton SM,Gordeuk VR,Saraf SL,Calip GS

    更新日期:2019-04-01 00:00:00

  • A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.

    abstract::Polo-like kinases (Plks) play an important role in cell cycle checkpoint controls and are over-expressed in acute myeloid leukaemia (AML). BI 2536, a novel Plk inhibitor, induces mitotic arrest and apoptosis. In this phase I/II trial of BI 2536 in 68 elderly patients with relapsed/refractory AML, three schedules were ...

    journal_title:British journal of haematology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/bjh.12518

    authors: Müller-Tidow C,Bug G,Lübbert M,Krämer A,Krauter J,Valent P,Nachbaur D,Berdel WE,Ottmann OG,Fritsch H,Munzert G,Garin-Chesa P,Fleischer F,Taube T,Döhner H

    更新日期:2013-10-01 00:00:00

  • Telomere length is a critical determinant for survival in multiple myeloma.

    abstract::The variable clinical outcomes of Multiple Myeloma (MM) patients are incompletely defined by current prognostication tools. We examined the clinical utility of high-resolution telomere length analysis as a prognostic marker in MM. Cohort stratification, using a previously determined length threshold for telomere dysfu...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.14643

    authors: Hyatt S,Jones RE,Heppel NH,Grimstead JW,Fegan C,Jackson GH,Hills R,Allan JM,Pratt G,Pepper C,Baird DM

    更新日期:2017-07-01 00:00:00

  • Interleukin 2 enhances cytotoxic cell function in vitro after T-cell depleted marrow transplantation.

    abstract::After T-cell depleted marrow transplantation, there is a rapid recovery of cytotoxic effector cells, with activity against targets not susceptible to killing by 'resting' natural killer cells. These targets include Epstein-Barr virus transformed B cells and leukaemic cell lines. Activated killer cell function declines...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1987.tb02347.x

    authors: Leger O,Drexler HG,Reittie JE,Secker-Walker L,Prentice HG,Brenner MK

    更新日期:1987-11-01 00:00:00

  • Genomic organisation and regulation of murine alpha haemoglobin stabilising protein by erythroid Kruppel-like factor.

    abstract::Alpha haemoglobin stabilising protein (AHSP) binds free alpha-globin chains and plays an important role in the protection of red cells, particularly during beta-thalassaemia. Murine ASHP was discovered as a GATA-1 target gene and human AHSP is directly regulated by GATA-1. More recently, AHSP was rediscovered as a hig...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2006.06381.x

    authors: Keys JR,Tallack MR,Hodge DJ,Cridland SO,David R,Perkins AC

    更新日期:2007-01-01 00:00:00

  • A new type of hereditary persistence of fetal haemoglobin (HPFH): HPFH Tunisia beta + (+C-200)G gamma.

    abstract::Nd-HPFH are haematological conditions which are natural models to aid understanding of the haemoglobin (Hb) switch. In this paper we describe a new non-deletional hereditary persistence of fetal haemoglobin (nd-HPFH) associated with the highest Hb F level observed to date (up to 49% without haemopoietic stress). Seque...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:

    authors: Pissard S,M'rad A,Beuzard Y,Roméo PH

    更新日期:1996-10-01 00:00:00

  • Cumulative antiplatelet effect of low-dose enteric coated aspirin.

    abstract::Enteric coated aspirin (ECA) at doses of 325-1300 mg is an effective alternative to regular aspirin for inhibition of platelet activity while avoiding gastric irritation. The objectives of this study were to determine: (1) the lowest chronic dose of ECA providing effective inhibition of platelet activities, (2) the ti...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1985.tb07467.x

    authors: Jakubowski JA,Stampfer MJ,Vaillancourt R,Deykin D

    更新日期:1985-08-01 00:00:00

  • Thrombomodulin with the Asp468Tyr mutation is expressed on the cell surface with normal cofactor activity for protein C activation.

    abstract::Thrombomodulin (TM) is an endothelial cell glycoprotein that acts as an anticoagulant. Mutation in the TM gene is a potential risk factor for thrombosis. The first TM mutation identified was a heterozygous substitution of T for G at nucleotide position 1456, which predicted Asp468 with Tyr in a Ser/Thr-rich domain. To...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.1999.01567.x

    authors: Nakazawa F,Koyama T,Saito T,Shibakura M,Yoshinaga H,Chung DH,Kamiyama R,Hirosawa S

    更新日期:1999-08-01 00:00:00

  • Unique immunophenotype of acute promyelocytic leukaemia as defined by CD9 and CD68 antibodies.

    abstract::Twenty-one cases of acute promyelocytic leukaemia (FAB M3) demonstrating t(15,17) chromosomal translocation were studied in detail by immunocytochemical techniques using a panel of monoclonal antibodies. A characteristic myeloid phenotype of the leukaemic cells, co-expression of CD9 and CD68 antigens and absence of HL...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1994.tb04983.x

    authors: Erber WN,Asbahr H,Rule SA,Scott CS

    更新日期:1994-09-01 00:00:00

  • The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.

    abstract::Prospective studies in children with B-precursor acute lymphoblastic leukaemia (ALL) have shown that polymerase chain reaction (PCR)-based detection of minimal residual disease (MRD) using immunoglobin (Ig) and T-cell receptor (TCR) gene rearrangements as targets can be used to identify patients with a high relapse ri...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.2002.03228.x

    authors: de Haas V,Breunis WB,Dee R,Verhagen OJ,Kroes W,van Wering ER,van Dongen JJ,van den Berg H,van der Schoot CE

    更新日期:2002-01-01 00:00:00

  • Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.

    abstract::Pathogen reduction (PR) of platelet products increases costs and available clinical studies are equivocal with respect to clinical and haemostatic effectiveness. We conducted a multicentre, open-label, randomized, non-inferiority trial comparing the clinical effectiveness of buffy-coat derived leukoreduced platelet co...

    journal_title:British journal of haematology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2141.2010.08227.x

    authors: Kerkhoffs JL,van Putten WL,Novotny VM,Te Boekhorst PA,Schipperus MR,Zwaginga JJ,van Pampus LC,de Greef GE,Luten M,Huijgens PC,Brand A,van Rhenen DJ,Dutch - Belgian HOVON cooperative group.

    更新日期:2010-07-01 00:00:00

  • The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

    abstract::Terminal B-cell differentiation is a multi-step process, from short-lived plasmablasts to mature long-lived plasma cells (PC). The anti-apoptotic Bcl-2 family member Bfl-1/A1 plays a critical role in the survival of mature B cells. However, its potential involvement at the later stages of B-cell development remains hi...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.2004.04908.x

    authors: Tarte K,Jourdan M,Veyrune JL,Berberich I,Fiol G,Redal N,Shaughnessy J Jr,Klein B

    更新日期:2004-05-01 00:00:00

  • Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?

    abstract::Since cardiotoxicity is a life threatening late effect, a reduction of cardiotoxicity in the treatment of acute myeloid leukaemia (AML) is essential. This review is a compilation of the current knowledge about cardiotoxicity after AML treatment and of how future directions in treatment may affect its incidence. A tota...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/bjh.14374

    authors: Jarfelt M,Andersen NH,Hasle H

    更新日期:2016-11-01 00:00:00

  • A novel CSF-1 binding factor in a patient in complete remission following cytotoxic therapy for lymphoma.

    abstract::A novel colony stimulating factor-1 (CSF-1) binding factor present in the serum from a patient in remission from lymphoma is described. Radioimmunoassay (RIA) repeatedly failed to detect circulating levels of CSF-1 in the peripheral blood system of this patient. Molecular analysis showed a normal CSF-1 gene structure ...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1995.tb08937.x

    authors: Baker AH,Cachia PG,Tennant GB,Whittaker JA,White D,Stanley ER,Burnett AK,Padua RA

    更新日期:1995-01-01 00:00:00

  • Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.

    abstract::Platelet-derived growth factor (PDGF) is thought to play some role in the genesis of fibrosis associated with myeloproliferative disorders. In addition, transforming growth factor-beta (TGF-beta) has been confirmed to promote fibrotic process. Both PDGF and TGF-beta have been shown to cooperate with epidermal growth f...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1991.tb07952.x

    authors: Martyré MC,Magdelenat H,Bryckaert MC,Laine-Bidron C,Calvo F

    更新日期:1991-01-01 00:00:00

  • Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity

    abstract::Standard treatment for classical Hodgkin lymphoma (cHL) is poorly tolerated in older patients and results disappointing. We assessed safety and efficacy of brentuximab vedotin (BV), in previously untreated patients with cHL unfit for standard treatment due to age, frailty or comorbidity. The primary outcome was comple...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.17073

    authors: Gibb A,Pirrie SJ,Linton K,Warbey V,Paterson K,Davies AJ,Collins GP,Menne T,McKay P,Fields PA,Miall FM,Nagy E,Wheatley K,Reed R,Baricevic-Jones I,Barrington S,Radford J

    更新日期:2020-09-14 00:00:00

  • Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis.

    abstract::Karyotypic analysis was performed in a total of 69 patients with well-characterized idiopathic myelofibrosis. Karyotypic abnormalities were detected in 46% of cases examined during the chronic phase (29/63); with three abnormalities, del(13q), del(20q) and partial trisomy 1q, accounting for 75% of all abnormalities at...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1994.tb05076.x

    authors: Reilly JT,Wilson G,Barnett D,Watmore A,Potter A

    更新日期:1994-11-01 00:00:00

  • Combined somatic mutation and copy number analysis in the survival of familial CLL.

    abstract::Recurrent large-scale somatic copy number alterations (SCNAs), and somatic point mutations can be analysed to stratify patients with chronic lymphocytic leukaemia (CLL) into distinct prognostic groups. To investigate the relationship between SCNAs and somatic mutations, we performed whole-exome sequencing and single n...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.15239

    authors: Zhou W,Goldin L,Wang M,McMaster ML,Jones K,Burdett L,Chanock SJ,Yeager M,Dean M,Caporaso NE

    更新日期:2018-06-01 00:00:00

  • Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion.

    abstract::Losses in 13q as a sole abnormality confer a good prognosis in chronic lymphocytic leukaemia (CLL). Nevertheless, its heterogeneity has been demonstrated and the clinical significance of biallelic 13q deletions remains controversial. We compared the clinico-biological characteristics of a series of 627 patients harbou...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/bjh.12479

    authors: Puiggros A,Delgado J,Rodriguez-Vicente A,Collado R,Aventín A,Luño E,Grau J,Hernandez JÁ,Marugán I,Ardanaz M,González T,Valiente A,Osma M,Calasanz MJ,Sanzo C,Carrió A,Ortega M,Santacruz R,Abrisqueta P,Abella E,Bosc

    更新日期:2013-10-01 00:00:00

  • Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and platelet-reactive anti-HIV antibodies in thrombocytopenic narcotic addicts.

    abstract::The levels of platelet-associated Igs (PAIgs) and plasma circulating antiplatelet antibodies were evaluated by a flow cytometric immunofluorescence assay (FCIFA), an enzyme-linked immunoassay (ELISA), and a platelet radioactive antiglobulin test (PRAT), in a group of 45 human immunodeficiency virus (HIV)-infected intr...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2141.1996.00502.x

    authors: Gonzalez-Conejero R,Rivera J,Rosillo MC,Cano A,Rodriguez T,Vicente V

    更新日期:1996-05-01 00:00:00

  • Shedding of CD9 antigen by bone marrow cells from patients with acute lymphoblastic leukaemia.

    abstract::The levels of soluble CD9 antigen released into spent medium from bone marrow (BM) cells were assayed using a unique enzyme-linked immunosorbent assay. We demonstrated that a considerable amount of soluble CD9 antigen was consistently detected in the spent medium from CD9+ leukaemic blasts, but little from normal or r...

    journal_title:British journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2141.1992.tb02986.x

    authors: Komada Y,Zhang SL,Zhou YW,Shibata T,Azuma E,Sakurai M

    更新日期:1992-08-01 00:00:00

  • Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.

    abstract::Chronic immune thrombocytopenia (ITP) is a haematological disorder in which patients predominantly develop skin and mucosal bleeding. Early studies suggested ITP was primarily due to immune-mediated peripheral platelet destruction. However, increasing evidence indicates that an additional component of this disorder is...

    journal_title:British journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2141.2009.07717.x

    authors: Nugent D,McMillan R,Nichol JL,Slichter SJ

    更新日期:2009-09-01 00:00:00

  • Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation.

    abstract::Patients with solid tumours undergoing high-dose chemotherapy with autologous bone marrow transplantation use an average of 10 units of packed red blood cells (PRBC) while awaiting haemopoietic reconstitution. They are also known to have inappropriately low endogenous erythropoietin levels for their degree of anaemia....

    journal_title:British journal of haematology

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2141.1994.tb04886.x

    authors: Ayash LJ,Elias A,Hunt M,Demetri G,Wheeler C,Tepler I,Schwartz G,Mazanet R,Reich E,McCauley M

    更新日期:1994-05-01 00:00:00